| Cancer | Eligard®, Camcevi®, Lupron depot®; Alymsys®, Avastin®, Avzivi®, Herceptin®, Hercessi®, Herceptin Hylecta™, Herzuma®; Riabni™, Ruxience®, Truxima™ | Camcevi®, Trazimera™ and other listed non-preferred oncology products per policy | Member must try designated preferred product(s) for the cancer category before IBX will cover a non-preferred product. |
| Colony-stimulating factors (long-acting) | Fulphila™, Neulasta® | Fylnetra™, Nyvepria®, Rolvedon®, Stimufend®, Udenyca®, Ziextenzo™ | Member must try designated preferred long-acting CSF prior to coverage of non-preferred long-acting CSF. |
| Colony-stimulating factors (short-acting) | Nivestym®, Zarxio® | Neupogen®, Granix®, Releuko® | Member must try designated preferred short-acting CSF prior to coverage of non-preferred short-acting CSF. |
| Denosumab products | Jubbonti®, Stoboclo®, Osenvelt®, Wyost® | Aukelso™, Bildyos®, Bilprevda®, Bomyntra®, Bosaya™, Connexence®, Enoby®, Ospomyv®, Prolia®, Xbryk®, Xgeva®, Xtrenbo® | Member must try designated preferred denosumab product(s) before denosumab-branded non-preferred products will be covered. |
| Eculizumab products | Epysqli® | Soliris®, Bkemv® | Member must try Epysqli® (preferred) before IBX will cover non-preferred eculizumab products. |
| Hyaluronate acid products | Monovisc®, Orthovisc®, Synvisc®, Synvisc-One® | Durolane®, Euflexxa™, Gel-One®, Gelsyn3™, GenVisc-850®, Hyalgan®, Hymovis®, Supartz®, Synojoynt™, Triluron™, TriVisc™, VISCO-3® | Member must try a plan-designated preferred hyaluronate product before coverage of non-preferred products in this class. |
| Infliximab products | Avsola™, Inflectra®, Infliximab (unbranded), Ixifi®, Remicade®, Renflexis® | (No separate non-preferred infliximab products listed; policy identifies preferred infliximab products) | Member must try a preferred infliximab product before IBX will cover a non-preferred infliximab product. |
| IV Iron | Preferred products (Level 1): All generic IV Iron (Feraheme®, Ferrlecit®, INFeD®, Venofer®) | Non-preferred products (Level 2): Injectafer®, Monoferric® | Member must try Level 1 preferred IV iron products before coverage of Level 2 non-preferred IV iron products. |
| Intravenous Immune Globulin (IVIG) | Bivigam®, Cutaquig®, Cuvitru®, Flebogamma®, Flebogamma DIF®, Gamastan S/D®, Gammagard Liquid®, Gammagard S/D®, Gammaked®, Gammaplex®, Gamunex-C®, Hizentra®, HyQvia®, Octagam®, Privigen®, Xembify®, Yimmugo® | Alyglo®, Asceniv®, Panzyga® | Member must try designated preferred IVIG product(s) before IBX will cover non-preferred IVIG products. |
| Myasthenia Gravis agents | Vyvgart®, Rystiggo® | Imaavy®, Ultomiris®, Epysqli®, Soliris®, Bkemv™ | Member must try Vyvgart® or Rystiggo® (preferred) before coverage of non-preferred MG agents. |
| Ophthalmologic VEGF agents | Preferred products (Level 1): Alymsys®, Avastin®, Avzivi®, Mvasi®, Vegzelma®, Zirabev® | Non-preferred products (Level 2 and 3): Byooviz™, Cimerli®, Lucentis® | Member must try a Level 1 preferred ophthalmologic VEGF product before IBX will cover Level 2/3 non-preferred ophthalmologic VEGF products. |
| Ustekinumab products | Yesintek™ | Imuldosa™, Otulfi®, Pyzchiva®, Selarsdi™, Starjezma®, Stelara®, Steqeyma®, Wezlana™ | Member must try Yesintek™ (preferred) before coverage of non-preferred ustekinumab products. |
| Tocilizumab products | Tyenne® | Actemra®, Avtozma®, Tofidence™ | Member must try Tyenne® (preferred) before IBX will cover non-preferred tocilizumab products. |